Since anti-PD1 Abs can be used for treating advanced MM even without BRAF mutations, anti-PD1 Ab-based regimens to treat advanced MM have recently been developed (Fujimura et al., 2020). This evidence concerns the gene BRAF and Miyoshi myopathy.